Hepatitis C Treatment: Most Medicare Beneficiaries Are Not Getting Authorized Generics
Executive Summary
The Office of the Inspector General finds that large rebates for higher-cost hepatitis C drugs and lack of formulary inclusion of authorized generics may be influencing the use of higher cost treatments in Medicare.